Health Professional Radio - Podcast

Returning guest, Dr. Steve Marcus, CEO of Cantex Pharmaceuticals, a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed discusses Azeliragon and the launch of investigator-led clinical studies focusing on a combination with radiosurgery in patients with brain metastases, front-line treatment for glioblastoma, metastatic pancreatic cancer and treatment of patients hospitalized with COVID-19 and pneumonia to prevent acute kidney injury.

#CantexPharmaceuticals

STEPHEN G. MARCUS, M.D., CHIEF EXECUTIVE OFFICER    Stephen G. Marcus, M.D. is a physician who has focused his professional career on the development of new treatments for cancer and other life-threatening and disabling diseases. Born and educated in New York City, Dr. Marcus received his medical degree from New York Medical College. After an internal medicine residency at Lenox Hill Hospital in New York, and oncology specialty training at the University of California in San Francisco, Dr. Marcus spent several years practicing emergency and critical care medicine and medical oncology.      

In 1985, Dr. Marcus entered the biotechnology industry where he has been directly responsible or played a critical role in the development of a number of important new medications. Dr. Marcus was the leader of the team of scientists and physicians who developed Betaseron as the first effective treatment of multiple sclerosis. This revolutionized the treatment of multiple sclerosis and was the forerunner of the many drugs for multiple sclerosis that are available today. Dr. Marcus played a key role in the development of fludarabine for a chronic lymphocytic leukemia, and served as the leader of multinational teams of researchers developing new treatments of cancer, multiple sclerosis, as well as other life-threatening or disabling conditions.

Dr. Michael R. Jaff, Vice President and Chief Medical Officer, Peripheral Interventions at Boston Scientific and Dr. Peter Monteleone, MD, FACC, FSCAI an interventional cardiologist and vascular medicine physician at Ascension Texas Cardiovascular in Austin, Texas and principal investigator of the REAL-PE study talk about the study results and the potential for real-world data to improve patient care in pulmonary embolism treatment and beyond.

#REALPEStudy #EKOS #Truveta

Michael R. Jaff, DO is the Vice President and Chief Medical Officer, Peripheral Interventions at Boston Scientific. A former professor of medicine at Harvard Medical School, Dr. Jaff was the President of Newton-Wellesley Hospital from October 2016-December 2019. Prior to that, Dr. Jaff was the inaugural Paul and Phyllis Fireman Endowed Chair of Vascular Medicine and Medical Director of the Fireman Vascular Center at the Massachusetts General Hospital. He is an expert in all aspects of vascular medicine, including peripheral artery disease, venous thromboembolic disease, aneurysmal diseases, and all diagnostic strategies in vascular medicine. He is the founder of VasCore, the Vascular Ultrasound Core Laboratory, the largest of its’ kind in the United States. VasCore has participated in trial design and independent analysis of vascular laboratory images for over 200 prospective multicenter peripheral vascular device and pharmaceutical trials across 66 countries. Dr. Jaff has published extensively in the field of Vascular Medicine with over 325 peer reviewed publications and 10 textbooks, is the Past-President of the Society for Vascular Medicine and Biology and was the first physician to have received the designation as Master of the Society for Vascular Medicine. He is a Fellow of the American College of Physicians, American College of Cardiology, the American Heart Association, and the Society for Cardiovascular Angiography and Intervention, and is a registered physician in vascular interpretation (RPVI).

David Berman, Head of Research and Development at Immunocore discusses the 3-year overall survival data from the  KIMMTRAK Phase 3 trial that  was presented at the European Society of Medical Oncology (ESMO) 2023  for their FDA approved treatment for uveal melanoma, a very deadly type of cancer in the eye. It was the first-ever approved treatment in the space.

#Immunocore

Dr. David Berman is Head of Research and Development. Over his career, David has worked on multiple immuno-oncology (IO) programs at all stages of development including leadership roles in developing four approved biologics. Most recently, David was Senior Vice President and Head of the AstraZeneca IO Franchise, responsible for the strategy and execution of the Company’s late stage IO program.   Prior to that, he was Head of the early stage oncology program at MedImmune. David has also held senior development roles at Bristol-Myers Squibb including as Head of the Immuno-oncology exploratory development team and global clinical lead for the first approved IO checkpoint inhibitor and one of the first monoclonal antibodies approved for myeloma. Beginning in academia and throughout his industry career, David has led efforts to understand the mechanism of action and predict benefit from IO therapies.

David received a Bachelor’s of Science from the Massachusetts Institute of Technology and MD and PhD from the University of Texas Southwestern Medical School. He trained in pathology at the National Cancer Institute followed by a fellowship at the Johns Hopkins Hospital.

Joan Lau, Ph.D., MBA, CEO of Spirovant Sciences discusses cystic fibrosis (CF) and how the standard of care right now addresses but does not correct the underlying cause of the disease. She talks about what needs to be done, and how her organization is working to revolutionize treatment for people living with CF by directly targeting and correcting the underlying cause of the disease.

#SpirovantSciences

Joan Lau is Chief Executive Officer of Philadelphia-based biotech Spirovant Sciences. She co-founded the company (then called Talee Bio), envisioning the potential for gene therapy for patients with inherited respiratory diseases. Under her leadership, Spirovant gained the support of the Cystic Fibrosis Foundation and was honored as PACT Healthcare Startup of the Year. Spirovant was acquired twice in 2019, once as part of a $3 billion transaction with Sumitomo Pharma.

Dr. Lau co-founded and is partner with Militia Hill Ventures, a firm focused on forming and growing life sciences companies. Previously she held roles as COO of Immunome (IMNM); President and CEO of Azelon Pharmaceuticals; and President and CEO of Locus Pharmaceuticals, a computational chemistry discovery company. VELEXBRU ® was discovered & developed at Locus under her leadership. Dr. Lau began her career at Merck Research Laboratories.

Dr. Lau has been recognized for her entrepreneurial accomplishments and leadership in the biotechnology industry and within the Philadelphia and social justice non-profit communities. She serves on the board for the Philadelphia Orchestra & Kimmel Center; the Penn School of Social Policy and Practice; Brandywine Realty Trust; and Rockwell Medical, Inc. She is an Adjunct Professor at Penn in the Wharton Healthcare Management Program. Previously she served as national board chair, Human Rights Campaign Foundation (DC). She was selected as the 2020 EY Entrepreneur of the Year, Philadelphia Region; a 2020 Woman of Distinction by the Philadelphia Business Journal; and the 2021 Iris Newman Award recipient from the Alliance for Women Entrepreneurs.

Dr. Lau earned an MBA from the Wharton School of Business and a BSE in Bioengineering, both at the University of Pennsylvania; and a PhD in Neuroscience from the University of Cincinnati College of Medicine.

Dr. Lishan Aklog, MD, Chairman and CEO of Lucid Diagnostics, a commercial-stage cancer prevention diagnostics company, discusses the company’s EsoGuard ® Esophageal DNA Test and EsoCheck ® Esophageal Cell Collection Device, the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer, targeting the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer.

#EsoGuard

Lishan Aklog, M.D. has served as Lucid’s Chairman and Chief Executive Officer since its IPO in October 2021 and previously served as its Executive Chairman since its inception in 2018. Dr. Aklog also

co-founded and has served as Chairman and Chief Executive Officer of Lucid’s parent company, PAVmed Inc (Nasdaq: PAVM) since its inception in 2014, and as Executive Chairman of PAVmed’s other major subsidiary, digital health company Veris Health Inc., since its inception.​

Dr. Aklog has been active in the life sciences for several decades, including as an executive, entrepreneur, public company director, technological innovator, corporate advisor, and, previously, as an innovator in cardiac surgery at leading academic medical centers, including Harvard Medical School and Mount Sinai School of Medicine. He is a medical technology industry leader who serves on the Board of Directors of the Advanced Medical Technology Association (AdvaMed), the world’s leading medical technology trade association, and was recognized as one the Top Healthcare Technology CEOs of 2021 by Healthcare Technology Report.​

Dr. Aklog began his career as a medical technology entrepreneur and executive in 2007, as co-founding Partner of both Pavilion Holdings Group (PHG), a medical device holding company, and Pavilion Medical Innovations (PMI), its venture-backed medical device incubator. He co-founded Vortex Medical Inc., a PHG portfolio company which developed and commercialized the revolutionary AngioVac ® system and served as its Chairman and Chief Technology Officer from its inception until its acquisition by AngioDynamics Inc. Dr. Aklog is an inventor on 35 issued patents and dozens of patent applications, including the patents of the AngioVac system and the majority of the PAVmed’s products. His patents have been honored by the Boston Museum of Science and the Boston Patent Lawyers Association.​

Dr. Aklog has served in various other capacities across the life sciences industry including on the Board of Directors and the Audit Committee of Contrafect Inc. (Nasdaq: CFRX), a biopharmaceutical company, and previously on the Board of Directors and as Chair of the Audit Committee of Viveon Health Acquisition Corp. (NYSE: VHAQ), a healthcare special purpose acquisition corporation (SPAC). Over his career, Dr. Aklog has served as a consultant to and on the Scientific Advisory Boards of numerous leading medical device companies, including Medtronic Inc., St. Jude Medical Inc., now Abbott Laboratories, Guidant Cardiac Surgery, now, Getinge AB, and Cardiovations, then, a division of Johnson & Johnson, as well as numerous early-stage medical technology companies. ​

Dr. Mary McGowan, MD, Chief Medical Officer at the Family Heart Foundation, discusses a recent study that revealed concerning findings showing the diagnosis and treatment of a rare genetic disorder, homozygous familial hypercholesterolemia (HoFH), is dangerously underdiagnosed and undertreated. Results published in the Journal of the American Heart Association (JAHA) by the Family Heart Foundation found that diagnosis of HoFH, a condition which can lead to severely elevated low-density lipoprotein cholesterol (LDL-C), often does not occur until a heart attack or other cardiac event.

#FamilyHeartFoundation

Mary P. McGowan, MD

Chief Medical Officer, Family Heart Foundation

Dr. Mary McGowan received her medical degree from the University of Massachusetts. She remained at the University of Massachusetts Medical Center for both internship and residency. She completed her fellowship at Johns Hopkins Hospital. Dr. McGowan is the Co-Director of the Lipid Clinic at Dartmouth Hitchcock Heart and Vascular Center. She is the author of numerous articles and five books. She has been the principal investigator on over 30 national and international clinical trials and has lectured widely in the United States, Canada, Europe and Asia on cholesterol metabolism. Dr. McGowan serves on the alumni board at the University of Massachusetts Medical Center and the National Lipid Association Foundation Board. She has previously served on the National Lipid Association Board of Directors, the NH Affiliate of the American Heart Association Board and was the first Chief Medical Officer of the Familial Hypercholesterolemia Foundation.

Jeremiah Robison, Founder and CEO of CIONIC discusses the company's success with the FDA-Cleared Cionic Neural Sleeve, the first bionic clothing to combine sensing, analysis, and augmentation to help individuals with neurological conditions like multiple sclerosis, stroke, and cerebral palsy live more freely and independently. CIONIC is now licensed to ship to over 90% of US states (and growing), with over 400 prescribing institutions and 200,000 hours of customer use.

#neurotech #multiplesclerosis #cerebralpalsy

Jeremiah Robison is the Founder and CEO of CIONIC, an innovative company that builds lightweight and durable bionic clothing driven by powerful algorithms that adapt in real-time to each individual's mobility needs. He started the company in 2018 after his daughter was diagnosed with cerebral palsy and he was frustrated at the lack of effective technology available to help improve her mobility. Four years later, CIONIC introduced the breakthrough, FDA-cleared Cionic Neural Sleeve, the first product to combine sensing, analysis and augmentation into a wearable garment. Prior to CIONIC, Jeremiah spent twenty years at the intersection of data, algorithms, and the human body, driving innovation in sensing and machine learning at Apple, Openwave Systems, Slide, and Jawbone. Jeremiah has a BS and MS in Computer Science from Stanford University.

Dr. Charles Vega, MD, Family Medicine Specialist and Director of Irvine’s Program in Medical Education for the Latino Community discusses Boehringer Ingelheim and Lilly’s launch of It Takes 2, a new health initiative to elevate the importance of complete testing and early diagnosis of kidney disease, particularly among those who have type 2 diabetes or high blood pressure and are at greater risk for it. Boehringer Ingelheim and Lilly partnered with musical artist Rob Base to release a remix of his ‘80’s hit song "It Takes Two" that underscores how It Takes 2 people – a patient and a healthcare professional – and two tests– eGFR and UACR – to detect kidney disease. View the “It Takes 2 – The Remix” music videos and access educational resources on the initiative’s website at CKDtesting.com.

#chronickidneydisease #kidneydisease #CKD

Charles Vega, M.D., is a family medicine specialist and Director of UC Irvine’s Program in Medical Education for the Latino Community. He has spent his entire 27-year medical career at UCI’s Family Health Center, the largest safety-net clinic in Orange County, where he teaches medical students and residents. His academic interests are focused on access to quality, compassionate medical care for underserved populations, and the development of training programs to promote this vision of healthcare. He is a member of various associations, including American Academy of Family Practice, California Academy of Family Physicians, California Medical Association and National Hispanic Medical Association.

Dr. Michael Boland, MD, PhD, Site Director, Mass Eye and Ear, Lexington, Medical Director, Practice Innovation for Ophthalmology, Massachusetts Eye and Ear and Associate Professor of Ophthalmology, Harvard Medical School discusses presentations from the 2023 American Academy of Ophthalmology annual meeting regarding AI and glaucoma.

#AAO2023 #AI #glaucoma

Dr. Boland is a member of the Glaucoma Service at Mass Eye and Ear and the Site Director at Mass Eye and Ear, Lexington. He has completed sub-specialty training in the medical and surgical management of glaucoma and is available for consultations for both glaucoma and cataracts. In addition to his clinical practice, Dr. Boland serves as Medical Director of Practice Innovation for Ophthalmology where he provides expert guidance on technology-based innovations that improve the quality of patient care and increase practice efficiency and safety. He has held national leadership positions related to information systems in ophthalmology and is uniquely qualified to embrace new innovations and accelerate the use of technology, including telemedicine.

Dr. Terence Rooney, Vice President, Rheumatology, Immunology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Development shares new data that was presented from the Phase 2a IRIS proof-of-concept study, demonstrating the efficacy and safety of nipocalimab in the first-ever clinical study of an FcRn inhibitor in adults living with moderate to severe rheumatoid arthritis, and supporting its progression into an anti-TNF combination study. These data were presented at the 2023 American College of Rheumatology (ACR) Convergence.

#ACR23 #Immunology #Rheumatology

Terence Rooney, M.D., is Vice President, Rheumatology, Immunology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Development, LLC. In this role, he is responsible for driving scientific leadership in the rheumatology disease area, overseeing innovative compounds across multiple phases of development. In his prior role at Janssen as Vice President, Immunology Clinical Development, Terence led the Late Development Clinical organization, overseeing all late-stage Immunology clinical trials. Under his leadership, the team delivered many important milestones, and evolved to meet the present and future needs of our growing and complex Immunology portfolio more sustainably. Prior to his time at Janssen, Terence held positions of increasing responsibility in translational/early and late clinical development at Roche and Eli Lilly, respectively. Terence received his medical degrees from the Royal College of Surgeons in Ireland. During 10 years of academic clinical practice at teaching hospitals in Dublin, he completed postgraduate training in Rheumatology and Internal Medicine. His clinical/translational research fields of interest included rheumatoid arthritis biomarkers for the evolving targeted therapy era, in which he acquired a doctoral degree. He completed a post-fellowship attachment at the University of California San Francisco Division of Rheumatology before transitioning to work full time in pharmaceutical research and development. Terence is based at the Spring House, Pennsylvania campus, and lives with his family in Gladwyne, Pennsylvania. Follow Terence on LinkedIn here.

https://www.annalsofoncology.org/article/S0923-7534(23)04015-2/fulltext and

https://www.nejm.org/doi/full/10.1056/NEJMoa2308849

#ESMO2023

Arlene O Siefker-Radtke, MD is a Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston, TX. She is a graduate of The Johns Hopkins University School of Medicine and has been in practice for more than 20 years.

On July 1, 2019, Dr. Chi was appointed Vice President and Chief Medical Officer, BC Cancer. Prior to this, he was the medical director of the Clinical Trials Unit at the BC Cancer Agency – Vancouver Centre. He was appointed Chair of the Genitourinary Systemic Group at the BC Cancer Agency in 2003. This group is responsible for developing systemic treatment management guidelines for patients with genitourinary cancers in the province of British Columbia (available at www.bccancer.bc.ca) and securing access to new therapies through the province’s health care system. Under his guidance as medical director of the Clinical Trials Unit at the BC Cancer Agency – Vancouver Centre (which provides access for patients to the latest in investigational new drugs through phase I, II and III clinical studies), the not-for-profit Clinical Trials Unit almost doubled patient accrual to trials, becoming a self-sustaining growth operation.

Dr. Chi is Professor with the Department of Medicine at the University of British Columbia. He is also the Co-Chair of the Genitourinary Disease Site for the Canadian Cancer Trials Group (CCTG) and the Canadian Uro-Oncology Group, which is responsible for developing the genitourinary cancer trials undertaken by investigators at a national cooperative group level. In addition, he is an Executive Committee Member and Past-Chair of the Investigational New Drug Site for the CCTG, which is responsible for developing early phase I/II trials across the CCTG disease sites.

Wensheng Fan, CEO and co-founder of Spectral AI, a company that is using artificial intelligence to revolutionize diagnostics and wound care, discusses the recently awarded Biomedical Advanced Research and Development Authority (BARDA) Project BioShield Contract. This contract is for the advanced development of the DeepView � System, the Company’s AI-driven burn wound imaging technology, to be used at emergency departments, trauma centers and burn centers, for both routine burn care and as a medical countermeasure for use in burn mass casualty incidents (BMCI). DeepView ® records imaging data of the wound and uses an AI algorithm to predict wound healing patterns based on a large proprietary clinical database.

#SpectralAI ​#AI #WoundHealing

Wensheng Fan

CEO and Co-Founder of Spectral AI, Inc., an award-winning, publicly traded predictive analytics company that develops proprietary artificial intelligence (AI) algorithms and optical technology for fast, accurate treatment decisions in wound care. Since launching the company in 2009, Wensheng has led engineering of the AI platform and DeepView ® product line, an FDA Breakthrough Designated medical imaging system, from concept and prototype to an FDA 501(K) cleared product, securing more than $150M in public and private funding to date.

Wensheng has 20 years of experience in pioneering market-disruptive natural speech recognition, real-time imaging systems, and AI driven predictive medical solutions. Before Spectral AI, Wensheng played pivotal roles in product development for start-up and large, international companies including Sensata Technologies, Navini Networks (acquired by Cisco), Precision Drilling Corporation (acquired by Weatherford), and Phillips Speech Processing.

Mr. Fan received his B.S.E.E. degree from Tsinghua University in Beijing, China and M.S.E.E. degree from Northeastern University in Boston.

Voyce is a technology-driven company dedicated to breaking down language barriers in healthcare. CEO of Voyce, Andrew Royce, discusses how the company delivers simple, seamless, and secure on-demand medical interpretation in more than 240 languages and dialects, 24/7. The app is designed to work with smartphones, tablets, laptops, desktops, iOS, Android, Telephonic and APIs. It is easily integrated into virtual care platforms and EMRs, such as EPIC, Teladoc, and Zoom.

#languageinterpreation #healthequity #healthcareenterprise

Andrew Royce, CEO of Voyce

Serving as a volunteer resettling Syrian refugees in Canada, Andrew Royce became acutely aware of the need for on-demand, medically qualified language interpreters that could reliably and confidentially support healthcare patients who don’t speak English. His passion for this service has been the catalyst behind Voyce. By putting the dignity of non-English speakers first and working to solve the pain points of those accessing language services through innovative new technologies, Royce has led the now global company to great commercial success and outstanding user satisfaction.

Voyce now supports about 5,000,000 conversations per year and created about 1,500 sustainable work opportunities for language interpreters in over 70 countries.

Jeff Hackman, CEO of Comera Life Sciences, discusses how the company uses its proprietary SQore™ viscosity reduction platform to transform intravenous (IV) biologics into subcutaneous (SQ) versions that patients can self-administer in a single dose. High viscosity is a significant hurdle to formulating subcutaneous biologics and Comera’s addition of excipients, such as caffeine, interrupts intermolecular interactions to reduce viscosity of high concentration monoclonal antibody formulations. These self-administered SQ biologics have significant potential benefits over IV infusion for patients and payers. Comera is leveraging its SQore platform in multiple ongoing collaborations with biopharma companies to enhance both commercial biologics and those in early development stages. For more information on Comera Life Sciences, visit https://comeralifesciences.com.

#biologics #formulation #drugdelivery

Jeffrey S. Hackman is Chairman and Chief Executive Officer of Comera Life Sciences. Prior to joining Comera, Jeff was President of US Operations for EUSA, a global pharmaceutical company focused on oncology and rare diseases. Previously, he had been acting CEO of Novelion Therapeutics, where he transformed the company to profitability. He joined Novelion from Shire Inc., where he had been Senior VP and Head of US Internal Medicine / Oncology Franchise. Previously, he established the North American oncology commercial division for Baxalta, following several years leading US commercial operations for Sigma Tau. He has also held senior roles in several other pharmaceutical companies.

Dr. ​Jeffrey Popma​, MD, Vice President and Chief Medical Officer for Coronary, Renal Denervation, and Structural Heart at Medtronic discusses Medtronic’s recent CE Mark approval for the Evolut™ FX TAVI System and the increased need for solutions for patients with symptomatic severe aortic stenosis.

#Medtronics #Hearthealth

Jeffrey Popma, MD, is the Vice President and Chief Medical Officer for Coronary, Renal Denervation, and Structural Heart at Medtronic, a position that he has held since June 2020. Dr. Popma received his BA in Economics from Stanford University and received an MD with the highest distinction from Indiana University School of Medicine. He completed his internship, residency, chief residency in Internal Medicine, and Cardiovascular Fellowship at the University of Texas Southwestern Medical Center in Dallas, TX. He also completed an Interventional Cardiology fellowship at the University of Michigan in Ann Arbor, MI. He has been former interventional faculty at Medstar Washington Hospital Center in Washington, DC and the Brigham and Women’s Hospital in Boston, MA. Dr. Popma was most recently the Director of Interventional Cardiology Clinical Services at the Beth Israel Deaconess Medical Center in Boston, MA, and a Professor of Medicine at Harvard Medical School. Dr. Popma was also the director of the BIDMC Imaging Core Laboratory which completed over 500 studies in coronary, renal denervation, peripheral vascular disease, and structural heart. Dr. Popma has been the national or local investigator for a broad array of new technology, including bare metal stents, drug eluting stents, distal protection devices, total occlusion devices, carotid and peripheral revascularization procedures, and transcatheter valve therapy. Dr. Popma is the Past President of the Society for Cardiac Angiography and Intervention, and a Past Co-Chair of the Interventional Council of the American College of Cardiology. Dr. Popma has served on the editorial boards of numerous publications. He has published over 500 peer-reviewed manuscripts.

Dr. Joe Kimura, Chief Medical Officer, discusses how Somatus deployed a robust transitions-of-care (TOC) service to help their patients safely transition from acute inpatient care to home. Somatus provides TOC services to CKD3/4/5 and ESKD patients and has found patients in the program are 49% less likely to be re-admitted to the hospital compared to usual care.   

#Health #Healthcare #Kidneycare

Dr. Kimura joins Somatus from Atrius Health, a 650+ physician Boston-based independent multispecialty practice serving 700,000 patients across Eastern MA. Transitioning after almost two decades from a Boston-based multispecialty group practice known as a national leader in value based accountable care, in his role as Somatus’ Chief Medical Officer, he is laser-focused on the provision of world class kidney care and works to help reduce the burden of end-stage-kidney disease in this country. Dr. Kimura works closely with our clinical care team leadership at Somatus to advance our clinical operations and improve patient outcomes as we continue to scale significantly across multiple markets and partner with providers and healthcare delivery systems to drive more healthy days at home.

He is board certified in Internal Medicine and Clinical Informatics and has been a national advocate for the practical applications of clinical informatics and healthcare analytics to improve care delivery. Dr. Kimura is a graduate of Stanford University, Washington University School of Medicine, and Harvard School of Public Health. He completed his residency training in primary care internal medicine at UCSF, his health services research fellowship at HMS, and the MIT Sloan Executive Program in Management, Innovation, and Technology in 2015. He is a faculty member in the Department of Population Medicine at Harvard Medical School.

Dr. Thomas Carroll, Director at Brigham and Women's Voice Program and the Medical Director of Otolaryngology Clinics at Brigham and Women's Hospital discusses his presentations from the 2023 American Academy of Head and Neck Surgery conference, hot topics, and current challenges in the field of ENT.

#AAOHNS #Brigham&Womens

Dr. Thomas Carroll is the Director at Brigham and Women's Voice Program and the Medical Director of Otolaryngology Clinics at Brigham and Women's Hospital. He is the President of the New England Chapter of the Voice Foundation. He is also the Assistant Professor in Otology and Laryngology at Harvard Medical School. He received his medical degree from Wright State University School of Medicine and completed a residency in otolaryngology at the University of Colorado Denver and Health Sciences Center. He then completed a fellowship in laryngology and care of the professional voice at the University of Pittsburgh Medical Center Voice Center.

Wendy Vogel, executive director of the Advanced Practitioner Society for Hematology and Oncology (APSHO) discusses the Make It HAPPen™ campaign and the recent survey that validated the impact APPs have on multiple myeloma patient journeys as well as the need to provide APPs with further educational resources.

#MakeItHappen #APPs #APSHO

Wendy H. Vogel, MSN, FNP, AOCNP ®, Harborside

Executive Director

Wendy H. Vogel, MSN, FNP, AOCNP ®, is an oncology nurse practitioner from Kingsport, Tennessee. She received her Bachelor of Science in Nursing at Tennessee Technological University and her Master of Science in Nursing in the Family Nurse Practitioner Program at East Tennessee State University. Ms. Vogel is a board- certified advanced oncology certified nurse practitioner through the Oncology Nursing Certification Corporation and a certified family nurse practitioner through the American Nurses Credentialing Center.

As well as being the Executive Director and a founding Board member of APSHO (the Advanced Practitioner Society for Hematology and Oncology) , Ms. Vogel is an Associate Editor of JADPRO and has published in several professional journals. She received the 2012 ONS Mary Nowotny Excellence in Cancer Nursing Education Award as well as the American Journal of Nursing Book of the Year Award for co-editing the Advanced Oncology Nursing Certification Review and Resource Manual: Instructor’s Resource. She has lectured nationally and internationally on oncologic topics and the role of the advanced practitioner.

Dr. Dan Faden, Specialist and Investigator in Head and Neck Surgery at Massachusetts General Brigham Mass Eye & Ear discusses his presentations from the 2023 American Academy of Head and Neck Surgery conference titled Ten Hot Topics in Head and Neck Surgical Oncology Panel and Great Debates: ctDNA: Is It Ready for Prime Time?

#AAOHNS #HeadAndNeckSurgery #MassGeneralBrigham

Dr. Dan Faden is a specialist, investigator, and surgeon, for the Mike Toth Head and Neck Cancer Research Center at Massachusetts General Brigham Mass Eye & Ear. He attended Harvard Medical School and is the Assistant Professor of Otolaryngology. Dr. Faden was the Howard Huges Medical Institute Research Scholar at the National Institute of Health/National Human Genome Research Institute. He completed residency training in otolaryngology–head and neck surgery at the University of California, San Francisco before completing two clinical fellowships in advanced head and neck oncologic surgery and cranial base surgery at the University of Pittsburgh Medical Center.

Dave Hering, CEO of  Invivyd, Inc, a biopharmaceutical company discusses the development of a monoclonal antibody to prevent COVID-19 in immunocompromised people, through their pivotal Phase 3 trial called CANOPY.    This is the final step in a rapid development program for an antibody infusion to prevent symptomatic COVID-19 in vulnerable populations.

#mAb

#COVID19 #immunocompromised

Dave Hering, M.B.A. has served as our Chief Executive Officer and a member of the Board of Directors since July 2022. He joined Invivyd in June 2021 and previously served as our Interim Chief Executive Officer and as our Chief Operating Officer. Prior to joining the Invivyd team, Dave held a variety of senior leadership roles in his six years at Pfizer, where he led the preparation and launch of Pfizer’s COVID-19 vaccine in the United States, including the initial contracts with the U.S. government. He also led Pfizer’s partnership with Gavi, the Vaccine Alliance, which supplies millions of vaccines to the developing world. Before Pfizer, Dave held several roles at Novartis, most notably serving on the front lines of the H1N1 pandemic and leading the Medical Counter Measures group. He holds an M.B.A. from Harvard Business School and a B.S. in Operations Research and Industrial Engineering from Cornell University.

Dr. Susan MacDonald, MD, board-certified ophthalmologist, Co-founder and CEO of Eye Corps discusses Eye Corps' mission to eliminate preventable blindness in sub-Saharan Africa through strategic partnerships with the local medical community and ophthalmic training institutions. Eye Corps works to build a sustainable infrastructure for eye care delivery in sub-Saharan Africa with a focus on eliminating gender inequity in vision care.

#TogetherInSight #humanitarian

#eyecare

Susan MacDonald, MD, Co-Founder, Eye Corps

Susan MacDonald is a board-certified ophthalmologist, receiving her medical degree from the University of Massachusetts Medical School. She trained in two specialties: Internal Medicine at Brown University and Ophthalmology Residency at the University of Utah.

At Brown, she helped develop a multi-specialty team to address medical and social barriers associated with AIDs. At the University of Utah, she fell in love with ophthalmic surgery and its ability to restore sight. The Moran Eye Center is where she found her purpose, her lifelong friends and amazing mentors. Returning to New England, she joined the Lahey Clinic Medical Center and Tufts School of Medicine clinical teaching program where she taught and treated patients for twenty-five years.

She is a member of the Academy of Ophthalmology and of the American Society of Cataract and Refractive Surgery (ASCRS). She has accepted the chair position of the ASCRS Foundation to support outreach in America and internationally. As a key thought leader, she is a senior advisor for two investment funds focusing on new technologies to improve health care in low- and middle-income countries.

In 2017, Susan co-founded Eye Corps, a nonprofit in sub-Saharan Africa. Within five years Eye Corps has grown from a small idea to a well-respected model of sustainable eye care. The goal of Eye Corps is to improve the quality and quantity of eye care provided by in-country professionals.

Andy DeLaO, Chief Strategy & Marketing Officer ​a​t GE HealthCare U.S. and Canada, discusses findings from "Reimagining Better Health," GE HealthCare's first-ever international study on the state of healthcare. The study amplifies the united perspectives of patients and clinicians who envision a more human and flexible healthcare experience.

#ReimaginingBetterHealth #GEHealthCare #futureofhealthcare

Andy DeLaO is the Chief Strategy & Marketing Officer for GE Healthcare’s business focused on building care at the n of 1 using the imaging gateway to precision health and care. He has a clinical background in radiation oncology and physics. He has led teams to design and run multiple cancer centers in the U.S. as well as 25 cancer centers and 150 risk reduction facilities globally. He sits on the Board of Directors for Avant Diagnostics. He sits on the American College of Radiology’s Patient and Family Centered Care Committee.

He had the privilege of giving the 2016 American College of Radiology’s Moreton Lecture where he encouraged radiologists to “Step Out of the Dark and Into The Light.” This lecture focused the American College of Radiology to begin educating the public on the importance of radiology and their care pf patients. He gave the 2019 TRS Charles Craig Lecture reminding radiologists to “Choose Wisely: Asclepius or Caduceus.” He facilitated the Women In Artificial Intelligence and Medicine panel discussion for Radiology Partners in 2020. He most recently gave the talk “Without Me There Is No Medicine” at the 2022 Society of Breast Imaging.

Andy continues to deliver key notes both internationally and nationally highlighting the inflection point of our time, patients and physicians have the opportunity to work together and to bring back the art of medicine.

Dr. Christoph Correll, Professor of Psychiatry at the Zucker School of Medicine discusses common misconceptions about schizophrenia and the challenges that people experience when managing this condition, including adherence to medication and the risk of relapse. Dr. Correll also discusses a recently-approved treatment for adults with schizophrenia called UZEDY™ (risperidone) extended-release injectable suspension, and new data that build on our existing knowledge about this treatment option.

#SchizophreniaAwareness

Christoph Correll, MD, is professor of psychiatry at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and a medical director of the Recognition and Prevention (RAP) program at Zucker Hillside Hospital. He also currently serves as professor and chair of the Department of Child and Adolescent Psychiatry at Charité University Medicine in Berlin, Germany. He completed his medical studies at the Free University of Berlin in Germany and Dundee University Medical School in Scotland. He is board certified in general psychiatry and child and adolescent psychiatry, having completed both residencies at Zucker Hillside Hospital in New York City. Since 1997, he has been conducting research in New York, and in 2017, began working in Germany again.

Professor Correll has authored and co-authored more than 700 journal articles. He has served on several expert consensus panels on the use of antipsychotics across a range of psychiatric disorders, is a reviewer for more than 70 peer-reviewed journals and an editorial board member of 12 scientific journals. Professor Correll is the Principal Investigator or Steering Committee member of several large, federally funded grants. He has received more than 30 national and international research awards and fellowships for his work. Since 2014, the year of inception of this metric, he has been listed each year by Thomson Reuters/Clarivate/Web of Science as one of “The most influential scientific minds” and “Top 1% cited scientists in the area of psychiatry.”

Professor Correll’s research and clinical work focus on the identification, characterization and psychopharmacological management of adults and youth with severe psychiatric disorders. His areas of expertise include schizophrenia, bipolar disorder, major depression and other psychotic, mood and autism/disruptive behavior spectrum disorders, ranging from the prodrome to first episode, multi-episode and refractory illness patients. His work focuses further on psychopharmacology, epidemiology, clinical trials, comparative effectiveness, meta-analyses, the risk–benefit evaluation of psychotropic medications, and the interface between physical health and mental health.

Dr. Michael Racke, a board-certified neurologist and medical director of neurology at Quest Diagnostics, discusses the advances in blood and other tests for Alzheimer's Disease. He’ll also talk about other practical ways to talk to healthcare providers about the disease, new research that shows how lifestyle changes may reduce risk, and questions people should ask their doctor to assess their own risk. For more information visit questforthecure.com

#QuestDiagnostics

Dr. Michael K. Racke is Medical Director for Neurology at Quest Diagnostics, the leading provider of diagnostic information services and provider of AD-Detect, a portfolio of blood tests for assessing Alzheimer’s risk. He is a leader in the field of neurology and has over three decades of leadership experience in academia and clinical practice and continues to serve on several national professional society committees. Dr. Racke is board certified and is a member of the American Academy of Neurology and American Associations of Immunologists.

Dr. Juan Vera, CEO of Marker Therapeutics, a clinical-stage immuno-oncology company focused on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications discusses the APOLLO trial that is investigating MT-601, a multi-tumor-associated antigen (multiTAA)-specific T cell product targeting six antigens, for the treatment of patients with lymphoma who have failed or are ineligible to receive anti-CD19 CAR T cell treatment.

#MarkerTherapeutics

For the past 19 years, Dr. Vera has worked extensively on developing novel T cell therapies for clinical applications and has an extensive expertise in performing research in the field of adoptive T cell therapy. Dr. Vera has made several contributions in the field, specifically in the areas of developing and streamlining therapeutic candidates from the research bench to the clinic and from academia to industry.

Dr. Vera is a co-founder of Marker Therapeutics and AlloVir, and he has previously collaborated with Celgene and Bluebird Bio in developing novel CAR T cell therapies.

Prior to his appointment as CEO, Dr. Vera served as the Chief Operating Officer and Chief Scientific Officer of Marker Therapeutics. Before joining Marker, Dr. Vera was Associate Professor in the Department of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston. He is a co-investigator on several clinical trials for T cell therapy in both infectious disease and cancer. Dr. Vera has published more than 30 articles and is a named inventor on 13 published patents.

In recognition of his work, Dr. Vera has received several prestigious awards including the Idea Development Award from the Department of Defense and Mentored Research Scholar Award from the American Cancer Society. Dr. Vera attained his M.D. from the University El Bosque in Bogota, Colombia.

Returning guest, Dr. Andrew Cutler, Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University and CEO of Florida Clinical Research Center, LLC discusses real-world data from the START study demonstrating favorable efficacy and adherence among people living with TD who used a 4-week titration kit to reach optimal dosing with AUSTEDO ® (deutetrabenazine).

Andrew J. Cutler, MD

Clinical Associate Professor of Psychiatry SUNY Upstate Medical University Syracuse, New York

CEO, Florida Clinical Research Center, LLC Bradenton, Florida  

Andrew J. Cutler, MD is the Chief Medical Officer at Neuroscience Education Institute in Carlsbad, CA and a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, NY. He works remotely from Lakewood Ranch, Florida. He holds a BS in Biology from Haverford College, and obtained his medical degree from the University of Virginia School of Medicine, where he was elected into the Alpha Omega Alpha (AOA) honor medical society. Dr Cutler completed his medical internship and residencies in both Internal Medicine and Psychiatry at the University of Virginia Health Sciences Center, where he also did research training in dopamine receptor pharmacology. He is board certified in Internal Medicine by the American Board of Internal Medicine and in Psychiatry by the American Board of Psychiatry and Neurology. He is also a Certified Physician Investigator (CPI) from the Association of Clinical Research Professionals (ACRP).  

Dr. Cutler has been conducting clinical research since 1993, and has been a Principal Investigator on over 400 clinical trials in a variety of CNS and medical indications, focusing on ADHD, Bipolar Disorder, Depression and Schizophrenia in children, adolescents and adults. He was an Assistant Professor of Psychiatry at the University of Chicago before moving to Florida and founding Florida Clinical Research Center (FCRC) in 1998. He sold FCRC to Meridien Research in 2016. He retired from Meridien as Executive VP and Chief Medical Officer in 2019. He has authored more than 100 peer-reviewed scientific articles and has presented more than 300 abstracts and posters at scientific meetings around the world. He is a peer reviewer for several prominent medical journals and has served on several editorial boards. He has chaired or attended over 250 medical and scientific advisory boards, delivered more than 3,000national and international pharmaceutical promotional talks, and over 300 continuing medical education(CME) and Grand rounds presentations. He has participated in more than 50 national satellite TV medical education broadcasts and led 200-plus national medical web conferences. Dr. Cutler consults extensively with pharmaceutical and biotechnology companies and serves on the board of the Neuroscience Education Institute.  

Dr. Cutler is a member of the American Psychiatric Association (APA), the Florida Psychiatric Society(FPS) and the American Medical Association (AMA). He is honored to be a Fellow of both the APA and the Academy of Psychosomatic Medicine. He has received many professional honors and awards, including the Merck Award for outstanding medical scholarship, the University of Virginia Pride Award for outstanding patient care, the William Sorum Award from the APA, the Outstanding Congressional Fellow Award from the 103rd US Congress, a citation from Florida Hospital for outstanding patient care, and the Distinguished Clinical Professional Award from the Central Florida Mental Health Associates.

David Longo, Co-Founder and CEO of Ordaōs, an AI-driven drug design company, discusses generative AI and how Ordaos is using AI to design novel and customized mini-proteins they refer to as miniPRO ™. They achieve this development through their Odaōs Design Engine which leverages continuous learning loops and proprietary data sets to translate human-defined product criteria into machine-designed mini-proteins which can be safer and more effective. David will discuss what HCPs need to know about AI, how it can benefit drug design and development, and how AI can help create better drugs, faster, at less cost, and lower risk, and what this means for them.

#Ordaōs

David Longo is the Co-Founder and Chief Executive Officer (CEO) of Ordaōs. As CEO of Ordaōs, Longo leads a strong scientific team to design novel mini-proteins that help drug hunters deliver safer and more effective treatments.

Longo brings to Ordaōs, broad experience in innovation and technology, that compel him to approach protein design in a unique way. His expertise in AI and machine learning is incorporated into Ordaōs’’ Design Engine, driving the rapid creation of never-before-seen mini-proteins with improved probability of more therapeutically effective candidates. Prior to Ordaōs, this entrepreneur led a series of companies which he grew into successful entities.

Longo has an MS in biotechnology from Harvard University, graduate certificates in AI, Machine Learning, Innovation and Technology from Stanford University and Massachusetts Institute of Technology (MIT), and a master’s Certificate in Music Production from Berklee College of Music. He has a Bachelor of Science in Computational Mathematics from Rochester Institute of Technology. David is a learner, triathlete, and an inspirational leader.

Aetion Chief Science Officer, Nicolle Gatto, Ph.D., M.P.H., shares how the organization leverages real-world evidence (RWE) to support research and development activities as well as regulatory decisions to inform healthcare’s most critical decisions, advance access to medications, and ultimately improve patient care.

#Aetion

Nicolle Gatto, Ph.D., M.P.H.

Chief Science Officer

Nicolle is an epidemiologist with 20 years of industry experience. She serves as a senior scientific voice ensuring appropriate and principled use of real-world data/evidence. She received her PhD from Columbia University in New York City. Prior to Aetion, Nicolle was the Group Head for Vaccines and Oncology with the Epidemiology Group at Pfizer. Nicolle is a Fellow of the International Society for Pharmacoepidemiology and an Adjunct Assistant Professor of Epidemiology at Columbia University and Tulane, teaching courses in pharmacoepidemiology, causal inference and confounding control methods.

For further information go to: https://dhrosmarin.com/

#Anxiety, #Mental Health, #Thriving

David H. Rosmarin, PhD, is the director of the Spirituality and Mental Health Program at McLean Hospital and an associate professor of psychology in the Department of Psychiatry at Harvard Medical School. He received his PhD in clinical psychology from Bowling Green State University under the mentorship of Kenneth I. Pargament, PhD, and he completed a pre-doctoral internship and post-doctoral fellowship at Harvard Medical School and McLean Hospital.

Dr. Rosmarin studies the relevance of spirituality to mental health, and he innovates methods for clinicians to address this area of life. He has published over 100 manuscripts, editorials, and chapters, and served as co-editor of the Handbook of Spirituality, Religion and Mental Health. Dr. Rosmarin’s work is regularly featured by the media and has appeared in CNN, NPR, Scientific American, the Boston Globe, the Wall Street Journal, and the New York Times.

Dr. Rosmarin approaches spirituality/religion as a clinician-scientist. He innovates effective methods for clinicians to address spiritual and religious issues in the practice of evidence-based care. He also evaluates models of how and why spirituality/religion might be functionally linked to mental disorders in both positive and negative ways.

Dr. Rosmarin’s full-length practice text, “Spirituality, Religion, and Cognitive-Behavioral Therapy: A Guide for Clinicians,” provides theoretical foundations as well as step-by-step guidance for practitioners. Based on this foundational work, Dr. Rosmarin has developed several clinical protocols, including spiritual psychotherapy for inpatient, residential, and intensive treatment (SPIRIT), which allows for provision of spiritually integrated care within acute psychiatric settings. SPIRIT has been provided to over 5,000 patients at McLean Hospital, offered by more than 20 clinicians. Findings from several recent studies show that the approach is well tolerated by clinically, religiously, and demographically diverse patients.

Dr. Rosmarin has also developed several psychometric measures to assess spirituality/religion. His approach in this line of work simplifies assessment of this domain, so that practitioners and scientists can quantify aspects of spiritual/religious life that are clinically relevant to mental health and distress. Some of his measures have been translated into Farsi, Spanish, and Hebrew.

Dr. Rosmarin is the co-editor of the “Handbook of Spirituality, Religion & Mental Health, 2nd Edition,” an authoritative volume that summarizes the past 20 years of clinical science on this topic. His own research has identified that faith in a spiritual being is associated with improved treatment outcomes for depressed patients, and such effects are mediated by trust in the treatment process. Conversely, spiritual struggles (e.g., belief that one is being unfairly punished by God) predict greater anxiety, as mediated by greater intolerance for uncertainty and ambiguity.

A subset of Dr. Rosmarin’s research has focused on cultural psychiatry within the Jewish community. He has evaluated patterns of symptoms and treatment, the effectiveness of cognitive behavior therapy, the relevance of spiritual struggles, and the prevalence and impact of sexual abuse among Orthodox Jews.

Dr. Rosmarin’s research and clinical work have received over $5,000,000 in support.

Jaideep Singh, Co-Founder and CEO of Ambee talks about his passion for the environment, helping people improve their lives, and the groundbreaking environmental data the company has uncovered and how they’re making it actionable with a tech service like Allegra Airways.

#Ambee

Jaideep Singh is CEO and co-founder at Ambee, a climate tech startup that provides businesses with accurate spatio-temporal insights on climate factors – pollen, emissions, air quality, wildfires – across the world. Jaideep previously founded and ran a startup supplying schools with sports and fitness programs. He scaled this to over 100 schools before exiting. Prior to that, he was a corporate lawyer, working with India’s largest law firm, Amarchand Mangaldas, and in-house counsel at Mylan. Jaideep is a lawyer – BA LLB (Hons.) – from the prestigious NALSAR law school in India, and has a double master’s degree in Law and Economics from the Erasmus University Rotterdam and University of Vienna.

Dr. Purvi Parikh, a renowned allergist at NYU Langone Health discusses the launch of Allegra's new, first-of-its-kind map app called Airways that guides users to their destinations with real-time cleaner routes (least amount of air pollution and pollen). It essentially identifies a cleaner air commuting route and the best routes to avoid, like the Waze traffic app, but for clean-route commuting.

#AllegraAirways

Dr. Purvi Parik: Dr. Purvi Parikh is an adult and pediatric allergist and immunologist. She is currently on faculty as Clinical Instructor of Medicine and Pediatrics at New York University School of Medicine. She completed her fellowship training in allergy and immunology at Albert Einstein College of Medicine’s Montefiore medical center Prior to that, she completed her residency at the The Cleveland Clinic Foundation in Cleveland, OH and she is board certified by the American Board of Internal Medicine and the American Board of Allergy and Immunology.

She completed her B.A. in political science at Emory University and received her M.D. from St. George’s University. Dr. Parikh has published articles in allergy, asthma and immunodeficiency syndromes in the Annals of Allergy, Asthma and Immunology as well as The Journal of Gastrointestinal Cancer and is currently writing a chapter for an otorhinolaryngology textbook.

Dr. Parikh has also presented oral and poster presentations at various national and international meetings such as the American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma, and Immunology, American Thoracic Society, Federation of Clinical Immunology Societies and World Association of Sarcoidosis and other Granulomatous diseases. She has an interest in treating immunodeficiency syndromes.

She is passionate about health policy and sits on the health and public policy committee for the American College of Physicians. She also is a board member and founder of the Share and Care Foundation’s young professional committee which raises money for underprivileged women and children in India.

She was recently named national media spokesperson for a non-profit patient advocacy group called the Allergy and Asthma Network and has made numerous press and TV appearances on their behalf.

Lora Sparkman, RN, BSN, MHA, VP, Partner, Clinical Solutions, Patient Safety and Quality at Relias and Nurse.com ambassador, discusses the current maternal mortality crisis and steps healthcare organizations can take to improve the quality of care.

#MaternalHealth #MaternalMortality #MaternalMentalHealth

Lora Sparkman, MHA, BSN, RN, VP, Partner, Clinical Solutions, Patient Safety and Quality at Relias, has been a nurse for 37 years, with 10 at the bedside and 27 in health administration. She has been a leader in patient safety and improvement for over 22 years, specifically focusing on using software and technology to advance healthcare education to improve the competency of clinicians, leading to improved patient outcomes. For the past five years, she has served as a clinical leader at Relias. Sparkman was recognized as a one of the Top 10 Women Leaders in Healthcare Software in 2022 by Becker’s and Top 25 Women Leaders in Healthcare Software by The Healthcare Technology Report. Additionally, she was featured in a mini docuseries on maternal mortality and the role of the nurse sponsored by BBC Storyworks and the International Council of Nurses in 2022.

Dr. David Stein, PhD, CEO and Director of Babson Diagnostics  discusses how  Babson is reimagining the blood testing process by only using only a pea-sized amount of blood collected from the finger. Babson’s BetterWay™  Blood Testing eco-system is unique because it brings medically accurate blood testing to the convenience of a retail pharmacy, empowering people to better take charge of their health.

#BloodTesting #BetterWay #Diagnostics

Dr. David Stein, Ph.D., Chief Executive Officer and Director

David Stein is the former global head of strategy and president of molecular diagnostics for Siemens Healthineers. His previous roles include CEO of Siemens' point of care business, head of strategy for the Diagnostics division, and global vice president of engineering within the Diagnostics division. Working alongside Eric Olson, he was instrumental in incubating Babson Diagnostics in the company’s earliest days. David is also the Board Chairman of PixCell Medical, Israel

Dr. Stein earned his Ph.D. in Engineering from Johns Hopkins University.

Norman E. Rosenthal is a psychiatrist and scientist who first described SAD in 1984 and pioneered light therapy as a treatment. Dr. Rosenthal is currently Clinical Professor of Psychiatry at Georgetown University School of Medicine and the author of several books, his most recent being Defeating SAD (Seasonal Affective Disorder): A Guide to Health and Happiness Through All Seasons

#SeasonalAffectiveDisorder

Norman E. Rosenthal is a world-renowned psychiatrist, public speaker, and best-selling author who is known for his innovative research and inspirational writings. He is currently Clinical Professor of Psychiatry at Georgetown University School of Medicine and is listed as one of the Best Doctors in America. Dr. Rosenthal has practiced psychiatry for over three decades, treating people with all manner of psychiatric and emotional health issues. He is also a motivational speaker and a personal and professional coach, working with people from all walks of life including CEOs, top athletes, and performing artists.

Rosenthal was born and raised in South Africa and did his medical training at the University of Witwatersrand, where he graduated with high honors. He immigrated to the US and did his psychiatric residency at Columbia in NYC before going to the National Institute of Health in Bethesda, Maryland, where he began his research career in earnest. His first major research contribution was to describe and name Seasonal Affective Disorder (SAD) and to develop light therapy as a treatment for this novel condition. SAD – and its milder variant, the Winter Blues – are now known to affect millions of people worldwide, many of whom have benefited from the light therapy that Dr. Rosenthal pioneered.

Dr. Rosenthal is a highly cited researcher who has written over 300 scholarly articles, and authored or co-authored eight popular books. These include Winter Blues, the New York Times bestseller Transcendence, and the Los Angeles Times bestseller The Gift of Adversity. Rosenthal has conducted numerous clinical trials of medications and alternative treatments, such as Transcendental Meditation for psychiatric disorders, and the treatment of depression with Botox. He and his work have been featured on Good Morning America, The Today Show, NPR and other national media.

Chad Worz, PharmD, BCGP, FASCP, Executive Director and Chief Executive Officer of the American Society of Consultant Pharmacists (ASCP) discusses a new flu vaccination campaign from the ASCP and Sanofi that encourages older adults and those with chronic conditions to speak with their healthcare providers or pharmacists about flu vaccine options that may be right for them.

#FluVaccine

Chad Worz, PharmD, BCGP, is the Chief Executive of ASCP. A board-certified geriatric pharmacist and graduate of the University of Cincinnati College of Pharmacy, his career has focused on the medication management of older adults. He developed an innovative clinical practice in a long-term care setting in Ohio and directed the pharmacy practice of a regional, independent pharmacy serving 10,000 long-term care residents. He established a nation-wide, geriatric-based consulting company to educate and serve nursing facility residents, nursing facility administration, long-term care pharmacies, and the public through a comprehensive knowledge of medication use. He is a national thought leader presenting on pharmacy and medication-related topics and has served on several national boards related to pharmacy and medication use. Chad’s hobbies include making furniture (sometimes for the ASCP office!), and the Star Wars movies are his favorite entertainment.

Dr. Steven Quay, Chairman of the Board and CEO of Atossa Therapeutics, a company focused on preventing breast cancer in at-risk women and treating breast cancer in women of all ages, discusses the development of a drug called (z)-endoxifen for breast cancer treatment which is currently undergoing 3 separate phase 2 clinical trials in the US.

#BreastCancer #Oncology #ClinicalTrials

Steven Quay is the founder of Seattle-based Atossa Therapeutics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions.

He received his M.D. and Ph.D. from The University of Michigan, was a postdoctoral fellow at MIT with Nobel Laureate H. Gobind Khorana, a resident at the Harvard-MGH Hospital, and was on the faculty of Stanford University School of Medicine. His contributions to medicine have been cited over 9,600 times.

He has founded six startups, invented seven FDA-approved pharmaceuticals, and holds 87 US patents. Over 80 million people have benefited from the medicines he invented.

His current passion is the prevention of the two million yearly breast cancer cases worldwide.

Sujal Shah, President and CEO of CymaBay Therapeutics, a clinical-stage biopharmaceutical company, discusses the positive topline results from its Phase 3 pivotal RESPONSE study of seladelpar in patients with primary biliary cholangitis (PBC), a rare, chronic inflammatory liver disease. This is the first potential therapy to show promise in significantly improving markers associated with risk of disease progression and significantly reducing itch.

#CymaBay

Sujal Shah – President and Chief Executive Officer

Mr. Shah has served as our President and Chief Executive Officer since March 2017. Previously, he served as our Chief Financial Officer since December of 2013. Prior to that he served as a consultant and acting Chief Financial Officer for us from June 2012 to December 2013. From 2010 to 2012, Mr. Shah served as Director, Health Care Investment Banking for Citigroup Inc., where he was responsible for managing client relationships and executing strategic and financing related transactions for clients focused in life sciences. From 2004 to 2010 Mr. Shah was employed with Credit-Suisse, last serving in the capacity as Vice President, Health Care Investment Banking Group. Mr. Shah currently serves on the Board of Tvardi Therapeutics, Inc. Mr. Shah received a M.B.A. from Carnegie Mellon University Tepper School of Business and M.S. and B.S. degrees in Biomedical Engineering from Northwestern University.

Michelle Wulfestieg, Executive Director at Southern California Hospice Foundation and CEO of Heavenly Home discusses how she is fighting the battle of homelessness for the terminally ill and how she is accepting those at Heavenly Home who may lack financial resources and have no other options for end-of-life care.

# SCHF

#SoCALHospice

#socalhospicefoundation

With the heart of a servant-leader, Michelle Wulfestieg is a two-time stroke survivor who understands just how precious life is and believes that as long as you are here, you have a purpose. Her own health struggles drew her to the field of Hospice where she has dedicated her life’s work for the last ten years, which is described in her award-winning book, All We Have Is Today: A Story of Discovering Purpose.

Since 2010, she has served as the Executive Director the Southern California Hospice Foundation, a non-profit organization committed to enhancing the lives of terminally ill patients and their families. Today, Michelle hopes to be an inspiration to those who are struggling. Her greatest wish for you is that you’ll find your true purpose, using the gifts you were given to change a life, to make a difference, to do good, to be all that you can be.

Returning guest, Dr. Paul Limburg, Chief Medical Officer, Screening at Exact Sciences discusses recent research that revealed countless reasons why 45-year-olds in the U.S. aren’t getting screened for this deadly condition despite recommendations by national screening guidelines. He talks more about how screening can change the course of this deadly disease.

#ExactSciences

Paul Limburg has served as our Chief Medical Officer, Screening since 2018. Dr. Limburg holds the academic rank of Professor of Medicine in the Mayo Clinic College of Medicine. His previous Mayo Clinic leadership roles include Co-Leader of the Cancer Prevention and Control Program, Medical Director for Global Business Solutions, Medical Director for the Office of Health & Well-Being, Physician Lead for Prediction & Prevention in the Center for Innovation, and Research Director for the Healthy Living Program, among others. Dr. Limburg has served on several enterprise-wide committees at Mayo Clinic, including the Management Team and the Clinical Practice Committee. Dr. Limburg is an inducted member of the American Society for Clinical Investigation and Sigma Xi honor societies and is a Fellow in the American Gastroenterological Association.

Dr. Limburg earned his BA degree in chemistry from Augustana College (Sioux Falls, SD), MD degree from Mayo Medical School, and MPH degree from the Johns Hopkins School of Hygiene and Public Health. He completed his Internal Medicine residency and Gastroenterology & Hepatology fellowship training at the Mayo Graduate School of Medicine. Dr. Limburg also completed an advanced fellowship in Preventive Oncology at the U. S. National Cancer Institute.

Tracy Curley, the CEO of iSpecimen, an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, discusses the iSpecimen platform, the importance of just-in-time biobanking and what’s up next for the industry. 

Tracy is an experienced, results-oriented business builder focused on leading iSpecimen’s vision for progressive financial performance, expansion and growth in today’s dynamic healthcare and biotechnology research markets.

Tracy brings three decades of experience in public accounting and corporate finance for both publicly traded companies and emerging companies like iSpecimen. Before joining iSpecimen, Tracy served as a partner at CohnReznick LLP, a national accounting firm, where she led the creation and development of an emerging markets commercial audit practice team focused on recruiting and providing audit services to private and public emerging growth companies in the technology and life sciences industries. Earlier, and as a partner at Marcum LLP, a national accounting firm, Tracy led the northeast regional high-tech practice for the firm with a focus on expanding the client base to provide a full range of accounting, tax and advisory services for private and public emerging growth companies in high tech industries such as technology, life sciences and advanced manufacturing. Tracy has also served as a partner at Moody, Famiglietti & Andronico, LLP (MFA), a proactive, Boston-based consulting firm with national and global reach, where she led the creation and development of a public company audit practice focused on recruiting and providing audit services to public emerging growth companies.

Tracy received her Master of Accountancy and Bachelor of Science in Business Administration with a concentration in accounting from Kansas State University. She also attended the United States Military Academy. She is a certified public accountant licensed in the Commonwealth of Massachusetts.

Dr. Deepak Bhatt, MD, MPH, Director of Mount Sinai Heart and Principal Study Author discusses the final dataset from the Phase 2 ENTRIGUE trial of 89bio’s pegozafermin in patients with severe hypertriglyceridemia (SHTG) that was published online in "Nature Medicine" (June 24, 2023). To learn more about pegozafermin’s indications in non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG), please visit https://www.89bio.com/pipeline/.

#SHTG #89bio #NatureMedicine

Deepak L. Bhatt MD, MPH, FACC, FAHA, MSCAI, FESC, is Director of Mount Sinai Heart and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai Health System.

After graduating as valedictorian from Boston Latin School, Dr. Bhatt obtained his science degree as a National Merit Scholar at MIT. He received his MD from Cornell and MPH from Harvard. He is working on his Executive MBA from Oxford. He trained in internal medicine at the University of Pennsylvania and in cardiology at Cleveland Clinic. He completed fellowships in interventional cardiology and cerebral and peripheral vascular intervention and served as Chief Interventional Fellow at Cleveland Clinic, where he spent many years as an interventional cardiologist, Associate Professor of Medicine, Director of the Interventional Cardiology Fellowship, Associate Director of the Cardiovascular Medicine Fellowship, and Associate Director of the Cardiovascular Coordinating Center. He then served as the Chief of Cardiology at VA Boston Healthcare System and subsequently as Executive Director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital. He was a Senior Investigator in the TIMI Study Group and Editor-in-Chief of the Harvard Heart Letter. He became a full Professor of Medicine at Harvard Medical School in 2012. He was selected by Brigham and Women’s Hospital as the 2014 Eugene Braunwald Scholar. He has been listed in Best Doctors in America from 2005 to 2020. He received the Research Mentor Award from Brigham and Women’s Hospital Department of Medicine in 2016, the Eugene Braunwald Teaching Award for Excellence in the Teaching of Clinical Cardiology from Brigham and Women’s Hospital in 2017, ACC’s Distinguished Mentor Award in 2018, AHA’s Distinguished Scientist Award in 2019, NLA’s Honorary Lifetime Membership Award in 2021, and SCAI’s Master designation in 2022.

Dr. Bhatt has authored or co-authored over 2000 publications and has been listed by the Web of Science Group as a Highly Cited Researcher from 2014 to 2022. He is the Editor of Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease and of Opie's Cardiovascular Drugs: A Companion to Braunwald's Heart Disease. He is one of the co-Editors of Braunwald’s Heart Disease. He is the Editor of the Journal of Invasive Cardiology. He had served as Senior Associate Editor for News and Clinical Trials for ACC.org and as a Trustee of the ACC.

Dr. Comilla Sasson, MD, PhD, Vice President for Healthcare Business Solutions at the American Heart Association and a practicing Emergency Medicine physician in Denver, Colorado discusses AHA’s newly launched Nation of Lifesavers™ initiative to double survival rates from sudden cardiac arrest by 2030. The new multi-year initiative will ensure teens and adults can learn about CPR and AED use, share that knowledge with friends and family and engage employers, policymakers, philanthropists, and others to create support for a nation of lifesavers. She talks about the do's and don'ts of CPR, including some common misconceptions, and shares some familiar songs from a variety of genres that can help everyone easily keep the correct pace when performing CPR

#CPR

Comilla Sasson, MD, PhD, received her M.D. from the University of Illinois at Chicago School of Medicine and completed her Emergency Medicine Residency at Emory University in Atlanta, GA. She received a Master of Science in Health and Health Services Research from the University of Michigan, Ann Arbor and completed her RWJ Clinical Scholars Fellowship in 2007-2010. She also received her PhD in Health Services Research in 2014 from the Colorado School of Public Health. Dr. Sasson is the Vice President for Health Science, Healthcare Business Solutions at the American Heart Association. She serves as a Special Advisor to the Pharmacy Benefits Management Medical Advisory Panel at the Veterans Health Administration. She is also a Clinical Associate Professor in the Colorado School of Public Health Department of Community and Behavioral Health and the Department of Psychiatry.